News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
558,648 Results
Type
Article (38920)
Company Profile (184)
Press Release (519544)
Section
Business (160676)
Career Advice (828)
Deals (26857)
Drug Delivery (71)
Drug Development (70427)
Employer Resources (78)
FDA (15046)
Job Trends (12401)
News (277198)
Policy (25912)
Tag
Academia (2353)
Alliances (44655)
Alzheimer's disease (1072)
Approvals (14972)
Artificial intelligence (156)
Bankruptcy (242)
Best Places to Work (10022)
Biotechnology (136)
Breast cancer (167)
Cancer (1225)
Cardiovascular disease (107)
Career advice (724)
CAR-T (90)
Cell therapy (257)
Clinical research (57033)
Collaboration (437)
Compensation (114)
COVID-19 (2306)
C-suite (103)
Data (1194)
Diabetes (145)
Diagnostics (5776)
Earnings (56579)
Events (78995)
Executive appointments (307)
FDA (15636)
Funding (363)
Gene therapy (171)
GLP-1 (575)
Government (3692)
Healthcare (16007)
Infectious disease (2393)
Inflammatory bowel disease (100)
Interviews (92)
IPO (11549)
Job creations (2748)
Job search strategy (656)
Layoffs (335)
Legal (5194)
Lung cancer (196)
Manufacturing (151)
Medical device (13916)
Medtech (13921)
Mergers & acquisitions (15426)
Metabolic disorders (410)
Neuroscience (1367)
NextGen Class of 2024 (5560)
Non-profit (3448)
Northern California (1263)
Obesity (232)
Opinion (131)
Patents (101)
People (47837)
Phase I (16615)
Phase II (25639)
Phase III (19953)
Pipeline (436)
Postmarket research (1988)
Preclinical (6248)
Radiopharmaceuticals (216)
Rare diseases (220)
Real estate (4786)
Regulatory (18325)
Research institute (2147)
Resumes & cover letters (121)
Southern California (1119)
Startups (3323)
United States (11824)
Vaccines (539)
Weight loss (180)
Date
Last 7 days (589)
Last 30 days (2145)
Last 365 days (29483)
2024 (28790)
2023 (33582)
2022 (44147)
2021 (47427)
2020 (46149)
2019 (40332)
2018 (30760)
2017 (28359)
2016 (27034)
2015 (31398)
2014 (23845)
2013 (20258)
2012 (21946)
2011 (22444)
2010 (20824)
Location
Africa (546)
Arizona (146)
Asia (35207)
Australia (6016)
California (2872)
Canada (1197)
China (267)
Colorado (144)
Connecticut (143)
Europe (76241)
Florida (448)
Georgia (117)
Illinois (312)
Indiana (185)
Kansas (94)
Maryland (552)
Massachusetts (2075)
Michigan (175)
Minnesota (236)
New Jersey (891)
New York (832)
North Carolina (612)
Northern California (1263)
Ohio (128)
Pennsylvania (690)
South America (811)
Southern California (1119)
Texas (430)
Utah (99)
Washington State (323)
558,648 Results for "nobles medical technology ii".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference
SeaStar Medical Holding Corporation announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time.
April 11, 2024
·
1 min read
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Subtle Medical Awarded Phase II Funding for SBIR Grant to Expand SubtleSYNTH™ Technology to Brain Imaging
September 5, 2024
·
2 min read
BioHarvest Sciences to Present at Noble Capital Markets Virtual Equity Conference on June 27, 2024
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will present at the Noble Capital Markets Virtual Equity Conference, being held June 26-27, 2024.
June 24, 2024
·
2 min read
Press Releases
Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2 and the Phase III MAVERIC-3 clinical trials
November 18, 2024
·
11 min read
Press Releases
BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024
November 21, 2024
·
3 min read
Press Releases
Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
November 21, 2024
·
1 min read
Clinical research
NuCana Shares Plummet as Another Chemotherapy Replacement Fails Phase II
NuCana’s chemotherapy replacement has failed to improve progression-free survival in a Phase II test, sending the biotech’s shares down by 50%.
August 30, 2024
·
1 min read
·
Annalee Armstrong
Press Releases
IN8bio to Present at Noble Capital Markets’ Twentieth Annual Emerging Growth Equity Conference
December 2, 2024
·
1 min read
Drug Development
Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab
On the heels of Keytruda’s success in a Phase III perioperative trial for a disease where it had previously failed to improve event-free survival, Merck touts an I&I deal with UK biotech Mestag.
October 8, 2024
·
2 min read
·
Kate Goodwin
1 of 55,865
Next
